Skip to main content
Erschienen in: Journal of Gastroenterology 6/2015

01.06.2015 | Editorial

How do we conquer the recurrence of HCC?

verfasst von: Kazuhiro Nouso

Erschienen in: Journal of Gastroenterology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Excerpt

According to recent advancements in imaging modalities and due to the prevalence of surveillance systems for hepatocellular carcinoma (HCC), early detection of HCC has been achieved, and the proportion of patients who can receive local ablation therapy or surgical resection is increasing. Although tumors seem to be treated completely, recurrence of HCC has been frequently observed at an annual incidence rate of approximately 20 %. To achieve long survival of patients with HCC, suppression of recurrence is mandatory. …
Literatur
1.
Zurück zum Zitat Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology. 2006;44(4):891–5 (Epub 2006/09/29).PubMedCrossRef Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology. 2006;44(4):891–5 (Epub 2006/09/29).PubMedCrossRef
2.
Zurück zum Zitat Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, et al. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol. 2014. doi:10.1007/s00535-014-0956-9. Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, et al. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol. 2014. doi:10.​1007/​s00535-014-0956-9.
3.
Zurück zum Zitat Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, et al. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol. 2014. doi:10.1007/s00535-014-0996-1. Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, et al. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol. 2014. doi:10.​1007/​s00535-014-0996-1.
4.
Zurück zum Zitat Honda M, Yamashita T, Yamashita T, Arai K, Sakai Y, Sakai A, et al. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013;13:191 (Epub 2013/04/17).PubMedCentralPubMedCrossRef Honda M, Yamashita T, Yamashita T, Arai K, Sakai Y, Sakai A, et al. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013;13:191 (Epub 2013/04/17).PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma prevention study group. New Engl J Med. 1996;334(24):1561–7 (Epub 1996/06/13).PubMedCrossRef Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma prevention study group. New Engl J Med. 1996;334(24):1561–7 (Epub 1996/06/13).PubMedCrossRef
Metadaten
Titel
How do we conquer the recurrence of HCC?
verfasst von
Kazuhiro Nouso
Publikationsdatum
01.06.2015
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 6/2015
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-014-1003-6

Weitere Artikel der Ausgabe 6/2015

Journal of Gastroenterology 6/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.